分子富集在肝细胞癌未来治疗中的作用
肝细胞癌具有显著的表型和分子异质性,多数患者合并肝病限制了积极治疗选择。近期III期临床试验证实抗血管生成治疗在晚期肝细胞癌一线(索拉非尼和仑伐替尼)和二线(瑞戈非尼和卡博替尼)均具价值,但过去10年多项大型随机对照试验失败,凸显创新治疗策略和转化研究实施的必要性。免疫治疗前景广阔但需不同患者管理方法和预后/预测生物标志物开发。基于临床和分子生物标志物的有效患者富集及适应性临床试验现已可行且应实施,本文综述精准医学方法在肝细胞癌临床试验中改善分子亚分类和开辟新治疗策略的重要方面。
要点
- 肝细胞癌表型和分子异质性显著,多数患者合并肝病限制积极治疗选择。
- III期试验证实抗血管生成治疗在晚期肝细胞癌一线(索拉非尼、仑伐替尼)和二线(瑞戈非尼、卡博替尼)均具价值。
- 过去10年多项大型随机对照试验失败,凸显创新治疗策略和转化研究实施的必要性。
核心结论
- 基于临床和分子生物标志物的有效患者富集及适应性临床试验现已可行且应实施,以改善肝细胞癌临床试验中的分子亚分类并开辟新治疗策略。
研究设计与样本
- 综述,旨在回顾肝细胞癌精准医学方法的重要方面,以改善临床试验中的分子亚分类并开辟新治疗策略。
主要发现
- 肝细胞癌具有显著的表型和分子异质性,多数患者合并肝病限制积极治疗选择。
- 近期III期临床试验阳性结果证实抗血管生成治疗在晚期肝细胞癌一线(索拉非尼和仑伐替尼)和二线(瑞戈非尼和卡博替尼)均具高价值。
- 过去10年多项大型随机对照临床试验失败,凸显创新治疗策略和转化研究实施以克服未满足临床需求的必要性。
- 新型免疫治疗的有前景结果可能补充肝细胞癌活性药物格局,将需要完全不同的患者管理方法和预后/预测生物标志物开发。
临床怎么用
- 基于临床和分子生物标志物的有效患者富集及适应性临床试验现已可行且应实施。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinomas (HCCs) are characterised by considerable phenotypic and molecular heterogeneity. Treating HCC and designing clinical trials are particularly challenging because co-existing liver disease, present in most patients, limits aggressive therapeutic options. Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities. However, failure of several large randomised controlled clinical trials over the last 10 years underlines the necessity for innovative treatment strategies and implementation of translational findings to overcome the unmet clinical need. Furthermore, the promising results from novel immunotherapies are likely to complement the landscape of active compounds for HCC and will require a completely different approach to patients, as well as the development of prognostic/predictive biomarkers. Given our increasing understanding of the most abundant molecular alterations in HCC, effective enrichment of patients based on clinical and molecular biomarkers, as well as adaptive clinical trials, are now feasible and should be implemented. Herein, we aim to review important aspects of precision medicine approaches in HCC that might contribute to improving the molecular subclassification of patients in a clinical trial setting and pave the way for novel therapeutic strategies.
引用
- Nault JC, Galle PR, Marquardt JU, et al. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018. PMID: 29505843. doi:10.1016/j.jhep.2018.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。